C反应蛋白/清蛋白比值对消化系统肿瘤患者预后评估价值的Meta分析

Meta-analysis of the prognostic value of C-reactive protein/albumin ratio in patients with digestive system carcinoma

目的探讨治疗前C反应蛋白/清蛋白比值(CAR)对消化系统肿瘤患者预后的评估价值。方法通过检索PubMed、Embase、Web of Science、Cochrane Library、中国知网、万方数据和中国生物医学文献数据库,搜索国内外公开发表的关于CAR与消化系统肿瘤患者预后相关的研究数据,检索时间范围从建库至2019年3月,采用STATA 12.0软件进行Meta分析,计算合并风险比(HR)。结果共纳入16项回顾性研究,包括3977例消化系统肿瘤患者。Meta分析结果显示,治疗前CAR水平与患者的总生存时间显著相关(HR=2.18,95%CI:1.81~2.63)。基于CAR临界值、肿瘤类型、治疗方案、样本量和肿瘤分期的亚组分析进一步表明,CAR高表达与消化系统肿瘤患者的不良预后存在相关性。结论治疗前CAR水平可作为消化系统肿瘤患者的预后指标。

Objective To explore the value of C-reactive protein/albumin ratio(CAR)before treatment in evaluating the prognosis of patients with digestive system carcinoma.Methods Search PubMed,Embase,Web of Science,Cochrane Library,CNKI,Wanfang Data and China Biomedical Literature Database to search for relevant data on the relationship between CAR and the prognosis of patients with digestive system carcinoma published at home and abroad,and the search time range From the establishment of the database to March 2019,STATA 12.0 software was used for Meta analysis to calculate the combined risk ratio(HR).Results A total of 16 retrospective studies were included,including 3977 patients with digestive system carcinoma.The meta-analysis results show that the CAR level before treatment is significantly related to the patient′s overall survival time(HR=2.18,95%CI:1.81-2.63).Subgroup analysis based on CAR cut-off value,tumor type,treatment plan,sample size,and tumor stage further showed that high CAR expression is related to the poor prognosis of patients with digestive system carcinoma.Conclusion CAR level before treatment can be used as a prognostic indicator for patients with digestive system carcinoma.